Trial
NCT02943642
Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides
Phase IIWITHDRAWNREGULATORYConfidence: MEDIUM
Sponsor
Virogen Biotechnology Inc.
Collaborators
City of Hope National Medical Center; Columbia University; Dana-Farber Cancer Institute; Northwestern University; H. Lee Moffitt Cancer Center and Research Institute; Ohio State University Comprehensive Cancer Center; Rush University Medical Center; Scott and White Hospital & Clinic; Yale University; Stanford University; Thomas Jefferson University; University of Arkansas; University of Colorado, Denver; University of Texas Southwestern Medical Center; University of Washington; Vanderbilt University School of Medicine; Washington University School of Medicine
Condition
Mycosis Fungoides
Intervention
A-dmDT390-bisFv(UCHT1)
Why stopped
This record is an earlier version (crossover design). After FDA-approved IND sponsor transfer to Virogen, the study was redesigned. This protocol will never start. The new protocol is NCT07529405.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-18